Loading…

Sartorius AGSRT.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical Specialties

German life sciences company making lab equipment and bioprocessing technology, majority owner of Sartorius Stedim Biotech.

Momentum leader 95
Mkt cap
$19.9B
US dollars, full cap
Free float
4%
of shares outstanding
$/day
$1.39M
20-day average traded
Fwd P/E
43.0×
forward earnings
ROIC−WACC
-2.8 pp
WACC 8.5%
Hurdle
+17 pp
Req g minus delivered
Official | Implied
BBB- / BBB
agencies · bond market
Next earnings
97 days
23 Feb 2027
Close · EUR€229.50
1D+1.6%
1W+0.2%
1M+10.1%
3M+17.0%
6M+25.7%
YTD+20.2%
1Y+30.6%
ATR %3.1%
52w lowhigh3.4% off high

What Sartorius does

German life sciences company making lab equipment and bioprocessing technology, majority owner of Sartorius Stedim Biotech.

Earns most of its revenue through Sartorius Stedim Biotech: equipment sold once, then consumables such as bags and filters bought again for every production batch. The smaller lab division sells balances, pipettes and filtration products to research and quality-control labs.

Products and services

  • Bioprocess solutions (via Sartorius Stedim stake)
  • Lab products & services (balances, filtration)

Customers

  • Biopharmaceutical manufacturers, research labs

Where it sits in the supply chain

  • Health Care
  • Life sciences tools
  • Lab equipment & bioprocessing…

What could go right

  • Biologics manufacturing capacity growth
  • Lab automation demand

What could go wrong

  • Post-COVID bioprocessing capex normalization
  • Customer capex cyclicality

Moat: narrow (switching costs, installed base, process know-how). Bioprocessing/lab equipment gets validated into customer workflows, creating switching costs.

Headquarters: Gottingen, Germany · Founded: 1870 · Employees: 14,042

Named competitors

Sartorius at a glance

Size Sartorius (SRT.DE) is a Germany Health Care company (Medical Specialties) with a market value of $19.9B, the 34th largest of 198 Germany companies the cockpit tracks. Shares closed at €229.50 on 18 Nov 2026.

Performance Over six months the shares gained 25.7%, against +25.3% for the median peer and -0.9% for the Germany market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 4.2% over the last twelve months (peer median +7.6%); the operating margin is 17.8% (peer median 17.4%).

Valuation It trades at 43.0× forward earnings against a peer median of 27.8× (6th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.8 points below its cost of capital (8.5% WACC).

Credit Sartorius has 4 bonds outstanding ($3.16B), rated BBB- by the agencies and trading like BBB at a weighted spread of 110 bp.

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026SRT.DE 125Peer median 122
Six months, rebased to 100: Sartorius against the median of its 20 peers (local-currency closes).

Sartorius financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€3.66B€3.54B€3.38B€3.40B€4.17B
Revenue growth—+5%0%-19%—
Gross profit€1.66B€1.64B€1.52B€1.57B€2.20B
EBITDA€1.08B€1.07B€995M€1.00B€1.48B
Net income€218M€155M€84.0M€206M€678M
Free cash flow€320M€214M€356M€186M€176M
Capital expenditure€399M€442M€410M€560M€523M
Total debt€3.91B€4.28B€4.56B€5.31B€2.54B

Quarterly statements and history in the cockpit →

Sartorius competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%SOONGHZBHSTMNRVTYCOLO-B4543DIMSTE688271WSTGKOSLENSKARTBAXDXCM7733PENSNILMN300760SRT.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Sartorius is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×SOONZBHSTMNRVTYCOLO-B4543DIM688271WSTGKOSLENSKARTBAXDXCMPENSRT.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sartorius is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SOONZBHSTMNRVTYCOLO-B4543DIMWSTLENSKARTBAXDXCM7733PENSNILMN300760SRT.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sartorius is the large dot.

Sartorius competitors and peer comparison

Head to head with its named competitors (SRT.DE vs DHR vs TMO vs MRK.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sartorius SRT.DE$19.9B+26%+4%18%43.0×25.6%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%
Repligen RGEN$11.0B+55%+14%9%71.0×56.9%

How Sartorius compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sartorius against its 20 peers (data as of 18 Nov 2026)
MeasureSRT.DEPeer medianRank in peer set
1-month return+10.1%+5.7%5th highest of 21
6-month return+25.7%+25.3%11th highest of 21
Distance from 52-week high-3.4%-11.1%5th highest of 21
Revenue growth (TTM)+4.2%+7.6%6th lowest of 21
Operating margin17.8%17.4%10th highest of 21
Forward P/E43.0×27.8×6th most expensive of 20
Growth the price implies (Req g, 7 yrs)25.6%14.0%7th most demanding of 18
Growth delivered (Del g)+8.7%+8.3%9th highest of 18
Hurdle (Req g minus delivered)+16.9 pp+4.2 pp6th most demanding of 18
ROIC minus cost of capital-2.8 pp+2.2 pp7th lowest of 21
EV / EBITDA21.3×18.5×8th most expensive of 17
Net debt / EBITDA3.4×0.8×2nd most indebted of 17
Bond spread110 bp94 bp3rd widest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%

Sartorius bonds and credit

Sartorius has 4 bonds outstanding with $3.16B face value. The agencies rate it BBB-; its bonds trade like BBB. Weighted yield 4.31%, a spread of 110 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Sartorius's main competitors?
Named competitors: Danaher (DHR), Thermo Fisher Scientific (TMO), Merck KGaA (MRK.DE), Repligen (RGEN). The cockpit's measured peer set (industry) also includes Sonova (SOON.SW), Guardant Health (GH), Zimmer Biomet (ZBH), Straumann (STMN.SW), Revvity (RVTY), Coloplast A/S (COLO-B.CO).
Is Sartorius expensive compared with its peers?
On forward p/e it trades at 43.0× against a peer median of 27.8×, 6th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sartorius stock performed?
Over six months to 18 Nov 2026 the shares returned +25.7% against +25.3% for the median peer; over one year +30.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.